163 related articles for article (PubMed ID: 32365629)
1. Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization.
Humphries MP; Bingham V; Abdullahi Sidi F; Craig SG; McQuaid S; James J; Salto-Tellez M
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32365629
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 Multiplex and Quantitative Image Analysis for Molecular Diagnostics.
Abdullahi Sidi F; Bingham V; Craig SG; McQuaid S; James J; Humphries MP; Salto-Tellez M
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33374775
[TBL] [Abstract][Full Text] [Related]
3. Validation of multiplex immunofluorescence and digital image analysis for programmed death-ligand 1 expression and immune cell assessment in non-small cell lung cancer: comparison with conventional immunohistochemistry.
Wu J; Mao L; Sun W; Yang X; Wang H; Liu X; Chi K; Huang X; Lin D
J Clin Pathol; 2022 Jul; 75(7):452-458. PubMed ID: 33782193
[TBL] [Abstract][Full Text] [Related]
4. Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities.
Humphries MP; McQuaid S; Craig SG; Bingham V; Maxwell P; Maurya M; McLean F; Sampson J; Higgins P; Greene C; James J; Salto-Tellez M
J Thorac Oncol; 2019 Jan; 14(1):45-53. PubMed ID: 30296485
[TBL] [Abstract][Full Text] [Related]
5. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS
J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400
[TBL] [Abstract][Full Text] [Related]
6. Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer.
Pang C; Yin L; Zhou X; Lei C; Tong R; Huang M; Gong Y; Ding Z; Xue J; Zhu J; Wang Y; Ren L; Zhou L; Wang J; Peng F; Zhou Q; Lu Y
J Thorac Dis; 2018 Feb; 10(2):816-824. PubMed ID: 29607153
[TBL] [Abstract][Full Text] [Related]
7. Visible- and near-infrared hyperspectral imaging for the quantitative analysis of PD-L1+ cells in human lymphomas: Comparison with fluorescent multiplex immunohistochemistry.
Brunner A; Willenbacher E; Willenbacher W; Zelger B; Zelger P; Huck CW; Pallua JD
Spectrochim Acta A Mol Biomol Spectrosc; 2023 Jan; 285():121940. PubMed ID: 36208576
[TBL] [Abstract][Full Text] [Related]
8. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
McLaughlin J; Han G; Schalper KA; Carvajal-Hausdorf D; Pelekanou V; Rehman J; Velcheti V; Herbst R; LoRusso P; Rimm DL
JAMA Oncol; 2016 Jan; 2(1):46-54. PubMed ID: 26562159
[TBL] [Abstract][Full Text] [Related]
9. Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study.
Taube JM; Roman K; Engle EL; Wang C; Ballesteros-Merino C; Jensen SM; McGuire J; Jiang M; Coltharp C; Remeniuk B; Wistuba I; Locke D; Parra ER; Fox BA; Rimm DL; Hoyt C
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34266881
[TBL] [Abstract][Full Text] [Related]
10. Comparison of laboratory-developed test & validated assay of programmed death ligand-1 immunohistochemistry in non-small-cell lung carcinoma.
Nambirajan A; Husain N; Shukla S; Kumar S; Jain D
Indian J Med Res; 2019 Oct; 150(4):376-384. PubMed ID: 31823919
[TBL] [Abstract][Full Text] [Related]
11. Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.
Smith J; Robida MD; Acosta K; Vennapusa B; Mistry A; Martin G; Yates A; Hnatyszyn HJ
Diagn Pathol; 2016 May; 11(1):44. PubMed ID: 27189072
[TBL] [Abstract][Full Text] [Related]
12. Comparison of different predictive biomarker testing assays for PD-1/PD-L1 checkpoint inhibitors response: a systematic review and network meta-analysis.
Shi H; Zhang W; Zhang L; Zheng Y; Dong T
Front Immunol; 2023; 14():1265202. PubMed ID: 37822932
[TBL] [Abstract][Full Text] [Related]
13. Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC.
Yeong J; Tan T; Chow ZL; Cheng Q; Lee B; Seet A; Lim JX; Lim JCT; Ong CCH; Thike AA; Saraf S; Tan BYC; Poh YC; Yee S; Liu J; Lim E; Iqbal J; Dent R; Tan PH
J Clin Pathol; 2020 Sep; 73(9):557-562. PubMed ID: 31969377
[TBL] [Abstract][Full Text] [Related]
14. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
15. Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation.
Lou SK; Ko HM; Kinoshita T; MacDonald S; Weiss J; Czarnecka-Kujawa K; Boerner SL; Yasufuku K; Tsao MS; Schwock J
Acta Cytol; 2020; 64(6):577-587. PubMed ID: 32599583
[TBL] [Abstract][Full Text] [Related]
16. Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis.
Widmaier M; Wiestler T; Walker J; Barker C; Scott ML; Sekhavati F; Budco A; Schneider K; Segerer FJ; Steele K; Rebelatto MC
Mod Pathol; 2020 Mar; 33(3):380-390. PubMed ID: 31527709
[TBL] [Abstract][Full Text] [Related]
17. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.
Scorer P; Scott M; Lawson N; Ratcliffe MJ; Barker C; Rebelatto MC; Walker J
Diagn Pathol; 2018 Jul; 13(1):47. PubMed ID: 30041679
[TBL] [Abstract][Full Text] [Related]
18. Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer.
Zerdes I; Karafousia V; Mezheyeuski A; Stogiannitsi M; Kuiper R; Moreno Ruiz P; Rassidakis G; Bergh J; Hatschek T; Foukakis T; Matikas A
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572882
[TBL] [Abstract][Full Text] [Related]
19. Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
Chauhan A; Siegel L; Freese R; Racila E; Stewart J; Amin K
Diagn Cytopathol; 2021 Mar; 49(3):355-362. PubMed ID: 33142053
[TBL] [Abstract][Full Text] [Related]
20. Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer.
Capizzi E; Ricci C; Giunchi F; Zagnoni S; Ceccarelli C; Gómez BUÁ; Casolari L; Gelsomino F; Trisolini R; Fiorentino M; Ardizzoni A
Lung Cancer; 2018 Dec; 126():9-14. PubMed ID: 30527198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
